Metastatic neck disease

2012 ◽  
pp. 661-689 ◽  
Author(s):  
Vinidh Paleri ◽  
John Watkinson
Keyword(s):  
Neck Disease

Pathologic Occult Neck Disease in Patients With Metastatic Cutaneous Squamous Cell Carcinoma to the Parotid

2011 ◽  
Vol 144 (4) ◽  
pp. 549-551 ◽  
Author(s):  
Diana N. Kirke ◽  
Sandro Porceddu ◽  
Benjamin D. Wallwork ◽  
Benedict Panizza ◽  
William B. Coman
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Neck Disease

Early Signs of Bladder-neck Disease

BMJ ◽  
1956 ◽  
Vol 1 (4972) ◽  
pp. 925-925
Author(s):  
W. M. Scott
Keyword(s):  
Bladder Neck ◽  
Early Signs ◽  
Neck Disease

scholarly journals Early Signs of Bladder-neck Disease

BMJ ◽  
1956 ◽  
Vol 1 (4968) ◽  
pp. 662-664 ◽  
Author(s):  
H. P. Winsbury-White
Keyword(s):  
Bladder Neck ◽  
Early Signs ◽  
Neck Disease

scholarly journals Mapping occipital bone thickness using computed tomography for safe screw placement

2015 ◽  
Vol 23 (2) ◽  
pp. 254-258 ◽  
Author(s):  
Tomonori Morita ◽  
Tsuneo Takebayashi ◽  
Hiroyuki Takashima ◽  
Mitsunori Yoshimoto ◽  
Kazunori Ida ◽  
...  
Keyword(s):  
Morphological Analysis ◽  
Reference Range ◽  
Occipital Bone ◽  
Institutional Review Board ◽  
Morphological Data ◽  
Screw Placement ◽  
Female Group ◽  
Bone Thickness ◽  
Institutional Review ◽  
Neck Disease

OBJECT Safe and effective insertion of occipital bone screws requires morphological analysis of the occipital bone, which is poorly documented in the literature. The authors of this study present morphological data for determining the area of screw placement for optimal internal fixation. METHODS The subjects of this institutional review board-approved retrospective study were 105 individuals without head and neck disease who underwent CT imaging at the authors’ hospital. There were 55 males and 50 females, with a mean age of 57.1 years (range 20–91 years). Measurements using CT were taken according to a matrix of 55 points following a grid with 1-cm spacing based on the external occipital protuberance (EOP). RESULTS The maximum thickness of the occipital bone was at the level of the EOP at 16.4 mm. Areas with thicknesses > 8 mm were more frequent at the EOP and up to 2 cm in all directions, as well as up to 1 cm in all directions at a height of 1 cm inferiorly, and up to 3 cm from the EOP inferiorly. The male group tended to have a thicker occipital bone than the female group, and the differences were significant around the EOP. The ratio of the trabecular bone to the occipital bone thickness was > 30% in the central region. At positions more than 2 cm laterally, the ratio was < 15%, and the ratio gradually decreased further laterally. CONCLUSIONS Screws that are 8 mm long can be placed in the area extending 2 cm laterally from the EOP at the level of the superior nuchal line and approximately 3 cm inferior to the center. These results suggest that it may be possible to effectively insert a screw over a wider area than the conventional reference range.

Outcomes with definitive local treatment to the primary site in non-nasopharyngeal head and neck squamous cell carcinoma patients with synchronous distant metastasis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18014-e18014
Author(s):  
Steven Borson ◽  
Yongli Shuai ◽  
Barton Branstetter ◽  
Marci Lee Nilsen ◽  
Marion Hughes ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Head And Neck ◽  
Distant Metastasis ◽  
Univariate Analysis ◽  
Local Treatment ◽  
Local Therapy ◽  
Distant Disease ◽  
Neck Disease ◽  
Metastatic Sites ◽  
Synchronous Distant Metastasis

e18014 Background: Data on the efficacy of including definitive local therapy to the primary head and neck disease (PHN) for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients with synchronous distant metastasis are lacking. Methods: In this single institution retrospective study, we evaluated the outcomes of patients treated from 2000-2020 at UPMC for non-nasopharyngeal HNSCC with synchronous distant metastasis whose therapy included definitive therapy to the PHN. We evaluated overall survival (OS), calculated as date of diagnosis to date of death and progression free survival (PFS), calculated as date of diagnosis to date of death or progression. Based on an initial univariate analysis, the potential significant predictors were evaluated further in the multiple covariates Cox model via stepwise procedures. The relative mortality rates were summarized with hazard ratio (HR), with HR > 1.0 corresponding to increased mortality. Results: A total of 40 patients met inclusion criteria. The median age was 61, primary sites included 52.5% oropharynx (48% HPV +), 40% larynx/hypopharynx, 7.5% oral cavity, and 85% had a solitary metastatic lesion, most commonly in the lung. Definitive treatment of the PHN was with surgery (55%) or chemoradiation (45%), and 45% also underwent local treatment for all distant disease. The median PFS was 8.6 months (95% CI, 6.4-11.6), and OS was 14.2 months (95% CI, 10.9-27.5). In the 28% of patients that received induction therapy, there was a two-fold increase in median OS to 27.5 vs. 13.7 months, p = 0.06. In the 33% of patients that received anti-PD-1 mAb immunotherapy (IO), the median OS was significantly increased to 41.7 months (95% CI, 8.7-NR) vs. 12.1 months (95% CI, 8.4-14.4), p = 0.01, with a numeric increase in PFS as well (11.3 vs. 8.2 months respectively, p = 0.07). Notably no difference in PFS or OS was seen with type of local therapy to the PHN, receipt of local treatment to all distant disease, by HPV status, or year of diagnosis. In multivariate analysis including induction and other variables significant in univariate analysis (age, number of metastatic sites), IO was independently associated with improved OS (HR 3.123 (No IO vs. IO) (95% CI, 1.198-8.137), p = 0.02), as was age and number of metastatic sites. In the patients that received IO started as part of induction the median PFS and OS were 19.5 and 45.5 months respectively. Conclusions: We observed impressive survival in select non-nasopharyngeal HNSCC patients with synchronous distant metastasis treated with definitive local therapy to the primary head and neck disease in addition to induction and/or IO, with IO independently associated with improved OS. To our knowledge this is the first evaluation of the efficacy of definitive local therapy and IO in this population. Prospective evaluation is warranted.

Sign in / Sign up

Export Citation Format

Share Document